-

12:54:33 PM

PHAT Stock News

PHAT - Phathom Pharmaceuticals Inc

05/25/22 8:00 AM

Nasdaq : PHAT

low float

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the U.S. Food and Drug Administration (FDA) has accepted for

RHEA-AI

positive

05/24/22 12:15 PM

Nasdaq : PHAT

low float

Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022

Results from an investigational Phase 3 PHALCON-EE trial demonstrating superior healing at week 2 in patients with LA Grade C/D (moderate-to-severe) erosive esophagitis and superior maintenance of healing at week 24 in all patients with vonoprazan versus lansoprazole shared in oral presentation 1

RHEA-AI

neutral

05/17/22 8:01 AM

Nasdaq : PHAT

conferenceslow float

Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting

New investigational data evaluating vonoprazan in erosive esophagitis (EE) Research highlights real-world evidence of unmet needs that exists for the treatment of Helicobacter pylori ( H. pylori) infection Phathom research recognized with multiple “posters of distinction” by American

RHEA-AI

very positive

05/10/22 8:00 AM

Nasdaq : PHAT

low float

Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates

U.S. Food and Drug Administration (FDA) approval received for VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for treatment of H. pylori infection in adults Up to $260 million revenue interest financing agreement strengthens balance

RHEA-AI

very positive

05/04/22 8:01 AM

Nasdaq : PHAT

low float

Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital

Upfront payment of $100 million, an additional $160 million available upon FDA approval of vonoprazan for treatment of erosive esophagitis (EE) Provides capital for launch of vonoprazan in H. pylori and EE, if approved, in addition to Phase 3 program in non-erosive reflux disease (NERD) Total

RHEA-AI

very positive

05/03/22 5:40 PM

Nasdaq : PHAT

fda approvallow float

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

VOQUEZNA TRIPLE and DUAL PAKs each contain vonoprazan, a novel, first-in-class potassium-competitive acid blocker (PCAB), and have demonstrated superior eradication rates vs. lansoprazole-based triple therapy in the overall patient population of the pivotal Phase 3 trial 1 VOQUEZNA treatment

RHEA-AI

neutral

04/26/22 8:00 AM

Nasdaq : PHAT

managementlow float

Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Frank Karbe to its Board of Directors. Mr.

RHEA-AI

neutral

04/01/22 8:01 AM

Nasdaq : PHAT

conferenceslow float

Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will

RHEA-AI

neutral

03/22/22 8:02 AM

Nasdaq : PHAT

managementlow float

Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to the

RHEA-AI

neutral

03/16/22 5:00 AM

Nasdaq : PHAT, ARQT

low float

Frazier Life Sciences Closes $987 Million Venture Fund to Invest in Companies Developing Novel Biopharmaceuticals

Frazier Life Sciences announced today the closing of Frazier Life Sciences XI, L.P., exceeding its target of $800 million and raising more than $987 million in capital commitments in an oversubscribed fundraise. FLS XI will be led by Managing Partners Patrick Heron and James Topper and General Partner Dan Estes, who have been with Frazier for 24, 20, and 12 years...

RHEA-AI

neutral